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Abstract 25 
Background: Hyperglycaemia is a common complication of prematurity and is associated with 26 
neonatal mortality and morbidity, yet the aetiology is incompletely understood. C-peptide has been 27 
used in adults to estimate endogenous insulin secretion due to its simple clearance kinetics.  28 
Objective: To determine insulin secretion calculated from plasma C-peptide concentrations in 29 
hyperglycaemic preterm babies. 30 
Methods: A retrospective analysis of a cohort of 41 very preterm babies (median gestational age, 31 
weeks: 27.2 (26.2-28.7)) enrolled in a randomised controlled trial of tight glycaemic control when 32 
they developed hyperglycaemia (2 consecutive blood glucose concentrations (BGC) > 8.5 mmol.L-1). 33 
Insulin secretion was determined using a steady state analysis of a 2 compartment C-peptide kinetic 34 
model. 35 
Results: BGC, plasma insulin concentration, plasma C-peptide concentrations and insulin secretion 36 
were higher at randomisation than 1-2 weeks following randomisation (p≤0.02). Insulin secretion was 37 
higher in girls (11.7 (5.3-18.7) vs. 4.7 (2.1-8.3) mU.L-1.kg-1.min-1, p<0.005) with no difference in 38 
clinical characteristics, BGC, plasma insulin concentration, or nutrition between the sexes (p>0.25). 39 
Insulin secretion was lower in samples taken during exogenous insulin delivery (3.7 (1.8 - 6.9) vs. 9.8 40 
(4.7 - 17.8)  mU.L-1.kg-1.min-1, p=0.02). 41 
Conclusions: Insulin secretion was higher when babies had higher BGC, indicating endogenous 42 
insulin secretion is sensitive to BGC. Girls had higher insulin secretion, at similar blood glucose and 43 
plasma insulin concentrations, than boys. 44 
Introduction 45 
Elevated blood glucose concentrations (BGC, hyperglycaemia) are a common complication of 46 
prematurity, affecting up to 80% of extremely low birth weight babies.[1] Hyperglycaemia has been 47 
associated with neonatal morbidity and mortality, but it is unknown if this is a causal 48 
relationship.[2,3]  Several studies have suggested that the cause of neonatal hyperglycaemia is 49 
multifactorial:  defective insulin production and relative insulin resistance;[4] incomplete suppression 50 
of endogenous glucose production,[5] and stress.[6] However, there are few data on the glycaemic 51 
regulation system in preterm babies.  52 
Insulin secretion in preterm babies, determined by plasma insulin concentrations, is responsive to 53 
systemic glucose and amino acids.[7] In adults, insulin secretion is increased by incretins, and 54 
suppressed by catecholamines and cortisol. Insulin is cleared by both the kidneys and the liver in a 55 
highly variable manner, as well as being cleared in peripheral tissues, making plasma insulin 56 
concentrations an inaccurate measure of insulin secretion. Pancreatic insulin secretion has been 57 
estimated in adults using models of C-peptide kinetics.[8] C-peptide is secreted in equimolar 58 
quantities with insulin, but is only cleared by the kidney. Therefore, the relatively simple kinetics of 59 
C-peptide provide a more accurate method of estimating insulin secretion. [8]  60 
This aim of this study was to determine insulin secretion, calculated retrospectively from plasma C-61 
Peptide concentrations, in preterm babies enrolled in a randomised controlled trial of tight glycaemic 62 
control[9] to determine predictors for insulin secretion in hyperglycaemic preterm babies.  63 
Methods 64 
Plasma samples were collected from 88 preterm babies during a prospective, randomised trial of tight 65 
glycaemic control of preterm babies (The HINT trial,[9] Australian Clinical Trials Registry 66 
12606000270516, ethics approval from Northern X ethics committee, written informed consent was 67 
obtained from a parent of each child). This trial compared tight glycaemic control (TGC) using insulin 68 
to maintain the BGC 4-6 mmol.L-1  in hyperglycaemic preterm babies, with standard care (control 69 
group), at the National Women’s Health NICU, New Zealand.[9] Babies were eligible for enrolment 70 
if they were born at <30 weeks’ gestational age (GA), or birth weight <1500g, and had become 71 
hyperglycaemic (two consecutive BGC measures >8.5 mmol.L-1 at least 4 hours apart). Babies were 72 
randomised when they became hyperglycaemic (usually 4-5 days postnatal age). Parenteral nutrition 73 
was commenced within the first day after birth and enteral feeds with small amounts of breastmilk 74 
were usually started in the first one to two days after birth. Small for GA was defined as less than the 75 
10th percentile on population based growth charts. Birthweight z scores were calculated based on a 76 
similar, New South Wales, published data cohort.[10] Lactose is comprised of both glucose and 77 
galactose (of approximately equal molar mass), with only glucose directly contributing to blood 78 
glucose concentration; therefore, glucose appearance from lactose was estimated as half the available 79 
lactose. 80 
Nutritional intake, BGC, growth and insulin infusions were recorded. Blood samples were taken at 81 
randomisation, 7 and 14 days post-randomisation, and at 36 weeks’ GA. Plasma insulin, insulin-like 82 
growth factor 1 (IGF-1), and glucose concentrations were measured, and remaining plasma samples 83 
were frozen. BGC were taken when clinically indicated and determined using a glucose oxidase 84 
method (ABL 700, Radiometer Ltd, Copenhagen, Denmark). Plasma insulin concentrations were 85 
measured on an Azsym system auto-analyzer (Abbott Laboratories, Abbott Park, IL).[9]  86 
Retrospective C-peptide analysis was carried out on samples with sufficient remaining plasma from 87 
samples taken 0-15 days after randomisation at a GA <32 weeks’. Plasma C-peptide concentrations 88 
were determined using immunometric assays (Elecsys 2010, Roche Diagnostics, Germany).  89 
Plasma  C-peptide concentrations were used to estimate insulin secretion, using the 2 compartment 90 
kinetics model:[8] 91 
𝑑𝐶
𝑑𝑡
= 𝑆 − (𝑘1 +  𝑘3)𝐶 + 𝑘2𝑌 (1) 
𝑑𝑌
𝑑𝑡
= 𝑘1𝐶 − 𝑘2𝑌 (2) 
Where C is the amount of C-peptide in the central compartment of plasma (and tissues in rapid 92 
equilibrium with the plasma), and Y is the amount of C-peptide in the peripheral extra vascular 93 
compartment. C-peptide (and insulin) is secreted into the central compartment at rate S. Transport of 94 
C-peptide from the central to the peripheral compartment, and back, is described by k1 and k2. 95 
Irreversible renal clearance of C-peptide from the central compartment via the kidney is modelled by 96 
k3.[8]  97 
A steady-state assumption can be made to enable deconvolution of the insulin secretion rate from 98 
measured C-peptide concentrations. Under this steady-state assumption, it follows from Equation 2 99 
that the rate of C-peptide entering and leaving the peripheral compartment must be equal. Hence, 100 
substituting this equality into Equation 1 and rearranging yields:  101 
𝑆 =  𝑘3𝐶 (3) 
 102 
Since insulin is secreted in equimolar quantities with C-peptide, under steady state conditions the rate 103 
of secretion of insulin is directly proportional to the measured concentration of C-peptide in the 104 
central compartment.  105 
Statistical Analysis 106 
Results are presented as median (IQR) or number (%) as appropriate. Non parametric data were log 107 
transformed to approximate normal distributions and compared using Student’s t test. The Lilliefors 108 
test was used to assess the results of the transformations. P-values < 0.05 were considered statistically 109 
significant.  110 
Results 111 
Of the 88 babies recruited to the trial, 41 were of GA<32 weeks’ and had sufficient plasma from 1 or 112 
more of the samples for further analysis, totalling 54 samples taken at a median of 7 days after 113 
randomisation. Of these 41 babies, 20 were from the tight glycaemic control group, contributing 25 114 
samples. Median birthweight was 839g and gestation was 27 weeks (Tables 1 and 2). 115 
BGC, plasma insulin, plasma C-peptide concentrations and insulin secretion decreased following 116 
randomisation (Figure). There was no difference between TGC and control groups in BGC (5.8[4.8-117 
11.0] vs. 8.0[5.3-10.6] mmol.L-1, p=0.27), plasma insulin concentration (14.3[8.0-27.6] vs 14.3[8.2-118 
27.6] mU.L-1, p=0.75), plasma IGF-1 (5.8[3.5-8.7] vs 7.1[3.9-9.3] ng.mL-1, p=0.83), C-peptide 119 
concentration (0.51[0.24-1.19] vs 0.98 [0.42-1.56] mmol.L-1, p=0.09), or insulin secretion (6.0[3.1-120 
11.8] vs 11.1[3.9-18.1] mU.L-1.kg-1.min-1, p=0.16). There were no differences in BGC, plasma insulin 121 
concentrations, and insulin secretion with ethnicity (p≥0.29). There was not a statistically significant 122 
correlation between insulin secretion and CRIB 2 score (r2=0.04, p=0.33) or plasma cortisol 123 
concentration at randomisation (r2=0.05, p=0.30). 124 
Of 54 samples, 41 were from singleton births. More babies from non-singleton birth were male (70% 125 
vs. 39%) but were similar in GA, weight, postnatal age and CRIB 2 score than babies from singleton 126 
birth (p>=0.69). The BGC was higher in the singleton group (8.6[5.6-11.1] vs. 5.5[4.8-7.5] mmol.L-1, 127 
p=0.03), but insulin secretion was not significantly different in babies from singleton compared with 128 
non-singleton births (9.1[3.7-19.4] vs. 5.1[3.2-10.2] mU.L-1.kg-1.min-1, p=0.28). 129 
Insulin secretion was higher in girls (Table 3). This difference was seen both at randomisation (18.0 130 
[13.3-27.1] vs. 6.7[3.5-9.4] mU.L-1.kg-1.min-1, p=0.01) and post randomisation (8.2 [4.8-13.0] vs. 3.6 131 
[1.2-7.6] mU.L-1.kg-1.min-1, p=0.03). There was no significant difference in insulin secretion between 132 
TGC and control groups for either sex (girls: 12.5[4.9-20.4] vs. 11.7 [8.0-17.4] mU.L-1.kg-1.min-1, 133 
p=0.81; boys: 4.7[1.8-7.3] vs. 6.5 [2.2-11.5] mU.L-1.kg-1.min-1, p=0.48). Clinical characteristics; BGC 134 
or plasma insulin concentrations; nutrition amount or delivery method were not different among the 135 
sexes (Table 3).  136 
Insulin secretion was lower at the time of samples taken during an insulin infusion (n=13) than when 137 
not on insulin infusion (3.7 [1.8-6.9] vs. 9.8[4.7-17.8] mU.kg-1.min-1, p=0.02) with no statistically 138 
significant effect on BGC (insulin infusion; 6.9[5.4-9.5] vs. not on insulin; 7.6[5.0-11.1] mmol.L-1, 139 
p=0.46) or plasma insulin concentration (insulin infusion; 19.9[9.2-26.7] vs. not on insulin; 13.2[6.6-140 
27.1]mU.L-1, p=0.25).  141 
At the time of the sample 47 infants (87%) received more than 80% of their total glucose via one 142 
feeding method: parenteral or enteral.  20 samples were from babies that received more than 80% of 143 
their total glucose delivery from enteral feeds (15.0[13.6-16.7] g.day-1 lactose), and 27 were from 144 
babies that were primarily receiving parenteral nutrition (8.3[5.9-9.8] g.day-1 glucose). The primarily 145 
enterally fed group were older at the time of the sample (17.5[15.8-19.3] vs. 5[3-7.5] days, p<0.005), 146 
and had a lower BGC (5.8[4.4-8.0] vs. 9.6[6.1-12.0] mmol.L-1, p=0.002). Protein intake on the day of 147 
sampling was greater in babies on enteral feeds (3.9[3.4-4.0] vs. 2.7[2.2-2.9] g, p<0.005). There was 148 
no statistically significant difference in insulin secretion between babies primarily receiving enteral or 149 
parenteral nutrition (8.3 [5.3-15.1] vs. 8.2[2.5-17.9] mU.L-1.kg-1.min-1, p=0.59). In the parenterally fed 150 
group insulin secretion was higher in girls (14/27 samples), (16.1[4.6-24.5] vs. 7.6[2.4-10.3] mU.L-151 
1.kg-1.min-1, p = 0.03), with no sex difference in BGC, dextrose or protein intake (data not shown).  152 
Discussion 153 
This study determined insulin secretion, calculated from plasma C-Peptide concentrations, in 154 
hyperglycaemic preterm babies randomised to tight glycaemic control or standard care. Insulin 155 
secretion in girls was more than double that in boys, despite similar clinical characteristics, plasma 156 
insulin and blood glucose concentrations, and no sex difference in the incidence of neonatal 157 
hyperglycaemia in babies eligible for the HINT trial.[9] The effect of sex on insulin secretion, as 158 
measured by C-peptide concentrations, has not been reported previously in preterm babies.[4] The 159 
relatively higher C-peptide and insulin secretion in females could reflect lower insulin sensitivity 160 
compared to males, or impaired renal clearance of C-peptide. We were unable to calculate the 161 
glomerular filtration rate (GFR) in these preterm babies, However, GFR has not been observed to be 162 
different between the sexes in preterm babies previously.[11] Several previous studies have also 163 
demonstrated sexual dimorphism in cardiovascular risk factors, such as blood pressure and heart rate 164 
variability, in preterm animals and babies.[12,13]  165 
This study used C-peptide measurements, data that relatively few studies have reported for this 166 
population.[4,14]  C-peptide concentration is a more accurate indicator of insulin secretion than 167 
plasma insulin concentration due to its simple clearance kinetics. In particular, C-peptide is only 168 
cleared through the kidney, in contrast to the multiple clearance paths of insulin.[8] Calculating the 169 
insulin secretion rate from C-Peptide concentrations deconvolves insulin secretion from insulin 170 
clearance and exogenous insulin inputs using a clinically well accepted approach.[8] It is more 171 
accurate than peak plasma insulin or area under the curve based methods, which examine net insulin 172 
turnover subject to a range of clearance routes. 173 
Differences in insulin concentrations and insulin sensitivity between the sexes have previously been 174 
observed during infancy and later in life. Plasma insulin and IGF-1 concentrations are higher in girls 175 
born at term than boys.[15] Women have been shown to have higher insulin sensitivity,[16] and post-176 
pubertal, pre-menopausal women are less likely than men to develop diabetes; a trend that reverses 177 
after menopause.[17] Potentially, the sex differences in insulin secretion seen in our study could be 178 
due to sex hormones, as oestrogen protects against beta cell apoptosis in mice[18] and oestrogen 179 
replacement therapy reduces the incidence of type 2 diabetes in post-menopausal women.[19]  180 
Preterm birth is associated with higher mortality, and poorer neurodevelopmental outcome in boys 181 
than girls.[20]  Animal studies have shown that in utero interventions, such as alterations of maternal 182 
diet, result in sexual dimorphism of cardiovascular risk factors, such as insulin resistance and raised 183 
blood pressure.[21] Recent studies have also shown sexual dimorphism in cardiovascular risk factors 184 
after preterm birth in both animal models and human studies.[12,13,22] Girls may respond differently 185 
to antenatal glucocorticoids, or preterm birth, than boys. Insulin sensitivity is reduced in children born 186 
preterm[23] and adults[24] exposed to antenatal glucocorticoids. Placental 11-hydroxysteroid 187 
dehydrogenase-2 activity following antenatal betamethasone is greater in girls than boys,[25] which 188 
may reduce the ability of betamethasone to increase insulin sensitivity in girls. As nearly all babies in 189 
this study were exposed to antenatal glucocorticoids it was not possible to analyse the effect of 190 
antenatal glucocorticoids on insulin secretion.  191 
Plasma insulin and C-peptide concentrations were also higher at randomisation, when all the babies 192 
were hyperglycaemic, suggesting that pancreatic insulin secretion in preterm babies is sensitive to 193 
BGC. Plasma insulin and C-peptide concentrations have previously been shown to decrease after 194 
insulin therapy to restore euglycaemia in a group of extremely preterm hyperglycaemic babies,[4] 195 
with similar C-peptide concentrations to the current study. In this study, insulin secretion was lower in 196 
babies receiving insulin infusion, suggesting suppression of endogenous secretion. However, there 197 
were insufficient samples to determine conclusively the effect of intravenous insulin therapy on 198 
endogenous insulin secretion.  199 
There was no statistically significant difference in insulin secretion between babies fed enterally or 200 
parenterally, indicating that enteral feeds may not increase insulin secretion in preterm babies. 201 
Previous studies have observed higher fasting and post-feed concentrations of glucagon-like peptide-202 
1, which has an incretin effect, in term and preterm babies,[26] but there are no data available on the 203 
effect of this on insulin secretion in preterm babies. In this study, we were unable to further 204 
investigate the effect of nutrition on insulin secretion in preterm babies due to the comparison of 205 
glucose (parenteral) and lactose (enteral), and the availability of daily totals of these sugars only. 206 
Moreover, babies receiving predominantly enteral feeds were more likely to be older than babies on 207 
parenteral feed. Insulin secretion is known to be enhanced or suppressed in adults by multiple 208 
variables, including BGC, nutritional intake and stress. Our finding of higher insulin secretion with 209 
higher BGC reflects other literature in preterm babies.[5] However, we did not find an association 210 
between insulin secretion and protein or total dextrose intake; plasma cortisol concentration, or route 211 
of nutrition administration. This lack of association may be due to the retrospective nature of this 212 
study, or may represent differences between preterm babies and adults which require further research.  213 
The major assumption required for the calculation of insulin secretion is that of steady state kinetics, 214 
an assumption which is considered necessary due to sampling limitations, as the small blood volume 215 
of extremely preterm babies limits the number of C-peptide measurements, and is reasonable in babies 216 
fed via parenteral infusions that do not tend to change dramatically from hour to hour. This 217 
assumption is perhaps less valid in enterally fed infants. However, when the analysis was repeated 218 
with samples only from infants who were mainly parenterally fed, the main study outcomes were 219 
unchanged. The study is also limited by its retrospective nature. However, given the scarcity of data in 220 
this extremely fragile cohort, it provides some insights into hyperglycaemic preterm infants otherwise 221 
not available.  222 
Girls had higher insulin secretion at similar blood glucose and plasma insulin concentrations to male 223 
babies. This may reflect a difference in insulin sensitivity in hyperglycaemic preterm girls. Therefore, 224 
interventions to prevent or treat neonatal hyperglycaemia may not be equally effective in girls and 225 
boys.   226 
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